These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10783805)

  • 1. The combination of population pharmacokinetic studies.
    Wakefield J; Rahman N
    Biometrics; 2000 Mar; 56(1):263-70. PubMed ID: 10783805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Bayesian analysis of a pivotal pharmacokinetic study.
    Rahman NJ; Wakefield JC; Stephens DA; Falcoz C
    Stat Methods Med Res; 1999 Sep; 8(3):195-216. PubMed ID: 10636335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects.
    Mackie AE; Ventresca GP; Fuller RW; Bye A
    Br J Clin Pharmacol; 1996 Jun; 41(6):539-42. PubMed ID: 8799519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung.
    Minto C; Li B; Tattam B; Brown K; Seale JP; Donnelly R
    Br J Clin Pharmacol; 2000 Aug; 50(2):116-24. PubMed ID: 10930963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in patients with mild-to-moderate asthma.
    Falcoz C; Horton J; Mackie AE; Harding SM; Daley-Yates PT
    Clin Pharmacokinet; 2000; 39 Suppl 1():31-7. PubMed ID: 11140431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study.
    Brutsche MH; Brutsche IC; Munawar M; Langley SJ; Masterson CM; Daley-Yates PT; Brown R; Custovic A; Woodcock A
    Lancet; 2000 Aug; 356(9229):556-61. PubMed ID: 10950233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration.
    Möllmann H; Wagner M; Meibohm B; Hochhaus G; Barth J; Stöckmann R; Krieg M; Weisser H; Falcoz C; Derendorf H
    Eur J Clin Pharmacol; 1998 Feb; 53(6):459-67. PubMed ID: 9551705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects.
    Möllmann H; Wagner M; Krishnaswami S; Dimova H; Tang Y; Falcoz C; Daley-Yates PT; Krieg M; Stöckmann R; Barth J; Lawlor C; Möllmann AC; Derendorf H; Hochhaus G
    J Clin Pharmacol; 2001 Dec; 41(12):1329-38. PubMed ID: 11762560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of fluticasone propionate nasal spray on the hypothalamic-pituitary-adrenal axis.
    Lipworth B; Jackson CM
    J Allergy Clin Immunol; 1999 Mar; 103(3 Pt 1):537-8. PubMed ID: 10069929
    [No Abstract]   [Full Text] [Related]  

  • 10. Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate.
    Rohatagi S; Bye A; Falcoz C; Mackie AE; Meibohm B; Möllmann H; Derendorf H
    J Clin Pharmacol; 1996 Oct; 36(10):938-41. PubMed ID: 8930781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gamma generalized linear models for pharmacokinetic data.
    Salway R; Wakefield J
    Biometrics; 2008 Jun; 64(2):620-6. PubMed ID: 17888039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects.
    Thorsson L; Dahlström K; Edsbäcker S; Källén A; Paulson J; Wirén JE
    Br J Clin Pharmacol; 1997 Feb; 43(2):155-61. PubMed ID: 9131947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the systemic availability of fluticasone propionate in healthy volunteers and patients with asthma.
    Daley-Yates PT; Tournant J; Kunka RL
    Clin Pharmacokinet; 2000; 39 Suppl 1():39-45. PubMed ID: 11140432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of fluticasone propionate.
    Sastre J
    J Investig Allergol Clin Immunol; 1997; 7(5):382-4. PubMed ID: 9416555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic bioavailability of inhaled steroids: the importance of appropriate and comparable methodology.
    Derendorf H; Daley-Yates PT; Pierre LN; Efthimiou J
    Eur Respir J; 2001 Jan; 17(1):157-8. PubMed ID: 11307748
    [No Abstract]   [Full Text] [Related]  

  • 16. Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane-134a beclomethasone in asthmatic patients.
    Leach CL; Kuehl PJ; Chand R; Ketai L; Norenberg JP; McDonald JD
    Ann Allergy Asthma Immunol; 2012 Mar; 108(3):195-200. PubMed ID: 22374204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between systemic exposure to fluticasone propionate and cortisol reduction in healthy male volunteers.
    Mackie AE; Bye A
    Clin Pharmacokinet; 2000; 39 Suppl 1():47-54. PubMed ID: 11140433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corticosteroid treatment of asthma: now at the crossroads. Reply to Drs Seale and Donnelly.
    Jolobe OM
    Respir Med; 1999 Feb; 93(2):145-6. PubMed ID: 10507942
    [No Abstract]   [Full Text] [Related]  

  • 19. Fluticasone and asthma.
    Edsbäcker S; Thorsson L
    Lancet; 2001 Mar; 357(9258):804. PubMed ID: 11253999
    [No Abstract]   [Full Text] [Related]  

  • 20. Corticosteroid treatment of asthma: now at the crossroads. Reply to Drs Seale and Donnelly.
    Dluhy RG
    Respir Med; 1999 Feb; 93(2):145. PubMed ID: 10507941
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.